Checkpoint Inhibitor-Induced Colitis: An Update
Immunotherapy with immune checkpoint inhibitors (ICIs) nowadays has indications for several solid tumors. The current targets for ICIs are CTLA-4, PD-1, and PD-L1 receptors. Despite the clinical advantages derived from ICIs, a variety of side effects are linked to overstimulation of the immune syste...
Main Authors: | Giuseppe Losurdo, Daniele Angelillo, Nicolas Favia, Maria Chiara Sergi, Alfredo Di Leo, Giacomo Triggiano, Marco Tucci |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/11/5/1496 |
Similar Items
-
Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management
by: Maria Terrin, et al.
Published: (2023-07-01) -
Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
by: Guanzhou Zhou, et al.
Published: (2022-10-01) -
Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options
by: Carmen Portenkirchner, et al.
Published: (2021-04-01) -
Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy
by: Aaron G. Issac, et al.
Published: (2022-06-01) -
The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review
by: Antonietta Gerarda Gravina, et al.
Published: (2024-01-01)